Published in Pain and Central Nervous System Week, March 31st, 2001
Delivery of cell or gene therapy to Duchenne muscular dystrophy patients has been stymied by the difficulty of injection directly into wasted muscles. Researchers working in Italy proposed to overcome that obstacle using intra-arterial injection of stem cells that could target lesions.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.